The WHO has given a green light to widespread use of GlaxoSmithKline's malaria vaccine in Africa, in what could be a major turning point in the fight against the disease. The RTS,S/AS01 vaccine ...

Being the only product on the market, GSK’s vaccine has dominated the shingles ... helping develop vaccines such as HPV-induced cervical cancer vaccine Cervarix (human papillomavirus bivalent vaccine) ...

Final results from a landmark study looking at the use of GSK's Mosquirix malaria vaccine alongside antimalarial drugs and other measures have shown a 90%-plus reduction in cases. The study in ...

The US Food and Drug Administration has put a clinical hold on BioNTech’s investigational new drug (IND) application and Phase I/II clinical trial examining the company’s pipeline malaria vaccine.

Expert Rev Vaccines. 2008;7(2):223-240. The EMVI is currently supporting preclinical activities at the Statens Serum Institute in Copenhagen and the Institut Pasteur in Paris for the development ...

The Trump administration intends to terminate the United States’ financial support for Gavi, the organization that has helped purchase critical ...

He spent nearly 30 years at GlaxoSmithKline, during which he helped shape its vaccine business by contributing to the creation of numerous new vaccines including Shingrix ® (shingles), Cervarix ® (HPV ...

Uganda has launched a malaria vaccination campaign in Apac District, northern Uganda. This makes Uganda the 19th country in Africa to introduce the malaria vaccine into routine immunisation, and it ...

BSI’s goal is to make QS-21 accessible to a wider range of vaccines and populations, particularly in low-income countries.

Curevo will use the funds for an extension of its Phase II programme to provide more dosing information for a Phase III trial. Image credit: Shutterstock / Stock Footage Inc. Curevo has set its sights ...